E-News - April 2025
Annual Scientific Meetings
 

Alliance RESEARCH At ASCO 2025

Alliance investigators will present more than 20 abstracts at the upcoming 61st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30–June 3, 2025, in Chicago and online. 

This year’s ASCO theme, “Driving Knowledge to Action: Building a Better Future,” emphasizes the vital connection between research and real-world improvements in cancer care. The meeting will spotlight key developments across the full continuum of cancer prevention, treatment, and survivorship—including significant developments in immunotherapy, precision medicine, and cancer control.
 
Alliance researchers will present abstracts, featuring the latest insights into breast cancer, rare cancers, and respiratory cancer, as well as gastrointestinal (GI), genitourinary (GU), and cancer control research. These studies represent the collective efforts of our community to improve outcomes and expand treatment options for patients.

PRESS BRIEFINGS AND FEATURED ABSTRACTS
Two ASCO press briefings will highlight research from the Plenary Session and Late-Breaking Abstracts (LBAs). Featured Alliance presentations include:

• Plenary Session
  • Abstract LBA1 – Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair colon cancer (Alliance A021502; ATOMIC)
• Late-Breaking Abstract
  • Abstract LBA3509 – Association between empirical dietary inflammatory pattern and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)

Additionally, the following, which includes Alliance data, will be featured in ASCO’s official Tip Sheet, which highlights noteworthy abstracts from across the meeting:

• Abstract 505 – 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials, assessing benefits of adjuvant exemestane + ovarian function suppression (OFS) or tamoxifen + OFS

• Embargo Information
  • General ASCO abstracts: Under embargo until Thursday, May 22 at 4 pm CDT
  • Plenary session and late-breaking abstracts (including the presentations above): Under embargo until Sunday, June 1 at 7 am CDT

ABSTRACT TITLES
Breast Cancer
Alliance A011401
Intervention adherence, engagement, and tool utilization in the Breast Cancer Weight Loss (BWEL) trial by race and ethnicity (Alliance)
Lead author: Ashley Odai-Afotey, MD
Abstract # 1586 | Poster Board # 352
Poster Session – Care Delivery/Models of Care
Learn more about the trial here.

Alliance A011401
Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial
Lead author: Caterina Sposetti, MD
Abstract # 561 | Poster Board # 154
Poster Session – Breast Cancer—Local/Regional/Adjuvant
Learn more about the trial here.

AFT-05
Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Lead author: Kristina Fanucci, MD
Abstract # 526 | Poster Board # 119
Poster Session – Breast Cancer—Local/Regional/Adjuvant
Learn more about the trial here.

CALGB 40603
Interferon signaling and outcomes in triple-negative breast cancer in the FinXX, CALGB 40603 (Alliance), and real-world clinico-genomic data
Lead author: Saranya Chumsri, MD
Abstract # 569 | Poster Board # 162
Poster Session – Breast Cancer—Local/Regional/Adjuvant
Learn more about the trials here (FinXX) and here.

IBCSG-24-02 (SOFT-TEXT), CALGB 40603
15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS
Lead author: Prudence Francis, MD
Abstract # 505
Oral Abstract Session – Breast Cancer—Local/Regional/Adjuvant
Learn more about the trials here (SOFT) and here.

IBCSG-25-02 (TEXT)
Assessment of ovarian function suppression (OFS)-containing adjuvant endocrine therapy in premenopausal women by Breast Cancer Index
Lead author: Ruth O'Regan, MD
Abstract # 557 | Poster Board # 150
Poster Session – Breast Cancer—Local/Regional/Adjuvant
Learn more about the trial here.

Experimental Therapeutics and Rare Tumor
Alliance A091802
A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC)
Lead author: Dan Zandberg, MD
Abstract # 6002
Oral Abstract Session – Head and Neck Cancer – Advanced/Metastatic Disease
Learn more about the trial here.

Alliance A092104
Alliance A092104 - A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy
Lead author: Brian Van Tine, MD
Abstract # 11507
Oral Abstract Session – Sarcoma – Soft Tissue Tumors
Learn more about the trial here.

Gastrointestinal Cancer
Alliance A021502
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair (Alliance A021502; ATOMIC)
Lead author: Frank Sinicrope, MD
Abstract #: LBA1
Plenary Session – Special Sessions – Colorectal Cancer – Local Regional Disease
June 1, 2025 1:05 pm-1:17 pm
Learn more about the trial here.
This abstract will be released to the public on June 1, 2025 at 7 am CDT

Alliance A021602
Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602)
Lead author: Amylou Dueck, PhD
Abstract # 4020
Rapid Oral Abstract – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Learn about the trial here.

Alliance A022104
Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC
Lead author: Caleah Kitchens, MD
Abstract # TPS3650 | Poster Board # 310b
Poster Session – Gastrointestinal Cancer—Colorectal and Anal — Colorectal Cancer–Local-Regional Disease
Learn more about the trial here.

Alliance A022101
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)
Lead author: Eric Miller, MD, PhD
Poster session for Gastrointestinal cancer – colorectal and anal.
Abstract # TPS3634 | Poster Board # 302b
Poster Session – Gastrointestinal Cancer—Colorectal and Anal — Colorectal Cancer–Local-Regional Disease
Learn more about the trial here.

CALGB 80405
Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405
Lead author: Francesca Battaglin, MD
Abstract # 3145 | Poster Board # 460
Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Learn more about the trial here.

CALGB 80405
The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials
Lead author: Marco Maria Germani, MD
Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Abstract # 3537 | Poster Board # 206
Learn more about the trial here.

CALGB 80405
Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials
Lead author: Marco Maria Germani, MD
Abstract # 3538 | Poster Board # 207
Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Learn more about the trial here.

CALGB 80405
Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405
Lead author: Michela Bartolini, MD
Abstract # 3128 | Poster Board # 443
Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Learn more about the trial here.

CALGB 80702
Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance)
Lead author: En Cheng, MD
Abstract # 3624 | Poster Board # 293
Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Learn more about the trial here.

CALGB 80702, NCCTG N0147
Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP)
Lead author: Qian Shi, PhD
Abstract # 3520
Rapid Oral Abstract Session – Gastrointestinal Cancer—Colorectal and Anal
Learn more about the trials here and here (N1047).

CALGB 80702, CALGB 150911
Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)
Lead author: Sara Char, MD
Abstract # LBA3509
Oral presentation - Clinical Science Symposium on "The Science of Survivorship for Colorectal Cancer"
Learn more about the trial here.

NCCTG N0147
Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)
Lead author: Frank Sinicrope, MD
Abstrac t# 3504
Oral Abstract Session – Gastrointestinal Cancer—Colorectal and Anal
Learn more about the trial here.

Genitourinary Cancer
Alliance A031704
Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (A031704) trial: results from Step 1 analysis
Lead author: Tian Zhang, MD
Abstract # 4516
Rapid Oral Abstract – Genitourinary Cancer—Kidney and Bladder
Learn more about the trial here.

Alliance A032102
Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker based study (Alliance A032102)
Lead author: Rana McKay, MD
Abstract # TPS5114 | Poster Board # 311a
Poster Session – Genitourinary Cancer—Prostate, Testicular, and Penile
Learn more about the trial here.

Respiratory Cancer
CTIU2317-A082305-S2402
Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402)
Lead author: Raid Aljumaily, MD
Abstract # TPS8113 | Poster Board # 234a
Poster Session – Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Learn more about the trial here.

Symptom Intervention
Alliance A221805
Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled phase II study
Lead author: Ellen Smith, PhD
Abstract # 12010
Rapid Oral Abstract – Symptom Science and Palliative Care
Learn more about the trial here.